Oscar Health Raises FY26 Operating Income Guidance by $100M, Improves MLR Outlook
OSCR has more than doubled off its 52-week low of $10.69.
Summary
Oscar Health raised its full-year 2026 operating income guidance by $100M to $600M-$800M and improved its medical loss ratio outlook by 50 bps to 81%-82%. This follows the Q2 earnings beat in August, where the company posted record profitability but shares fell on CFO comments about medical costs. The improved MLR outlook directly addresses that concern, signaling better cost control than previously expected. Revenue guidance was reaffirmed at $18.7B-$19B. The company will present its long-term strategy and updated targets at its Investor Day today at 9 a.m. ET, which could provide further catalysts.
At the time of this announcement, OSCR was trading at $32.50 on NYSE in the Finance sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $10.69 to $34.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.